I take medication for osteoporosis: can I have a dental implant, and what do I need to tell the dentist?

Why disclosing this medication matters

Dental implants are placed into the jawbone, so implant surgery is bone surgery. Osteoporosis medications that slow bone breakdown, called antiresorptives, include bisphosphonates taken as a weekly or monthly tablet, bisphosphonate infusions given every few months to once a year, and an injection given twice a year that blocks a bone signal called RANKL. A newer injectable, a sclerostin inhibitor, belongs in the same conversation. All of them change how bone remodels and heals, which is exactly what an implant relies on.

The concern is a condition called medication-related osteonecrosis of the jaw, or MRONJ. In plain terms, it is an area of jawbone that becomes exposed through the gum, or can be felt through a small opening, and does not heal within about eight weeks, in someone who takes or has taken one of these medications and has had neither radiation to the jaw nor cancer spread to the jawbone. It most often follows a procedure that disturbs bone, such as a tooth extraction, though it can occasionally appear with no dental trigger at all. Implant placement is a bone-invasive procedure, which is why this question belongs at the start of planning rather than after a surgery date is set.

Two things are worth saying plainly. First, the risk at osteoporosis doses is low, and professional guidance states that the fracture protection these medications provide generally outweighs it. Second, that means you should not stop or skip a dose because an implant is being considered; any change to the medication is a decision for the physician who prescribes it.

Why the dose and the reason for the medication matter so much

The same medication families are used in cancer care, usually by infusion, at doses many times higher and given far more often, to protect bone affected by cancer. The oral surgeons' association that publishes the main US guidance on MRONJ describes the risk as considerably higher in that group, quoting a figure below 5 percent, than in people treated for osteoporosis, where it quotes a figure below 0.05 percent. Those two situations are planned very differently, so the dentist's first questions are usually why the medication was prescribed, how it is given and for how long.

Duration matters within the osteoporosis group too. Risk appears to climb slowly with years of exposure, and the RANKL inhibitor injection is reported to carry a somewhat higher long-term risk than oral bisphosphonates. Bisphosphonates also remain bound in bone long after the last dose, so a tablet you stopped two years ago still belongs on your medication list.

The details that change the answer

Bring these to the consultation, or fill out the form at the end of this guide:

• The medication's generic name and class. Oral bisphosphonate, bisphosphonate infusion, RANKL inhibitor injection or sclerostin inhibitor injection. The pharmacy label or your patient portal shows the generic name.
• How it is given. Tablet, infusion or twice-yearly injection, and how often. Route and schedule change the risk picture and the timing options.
• When you started, and whether you ever stopped. Longer exposure, usually described as more than a few years, is weighed differently from a recent start.
• Why it was prescribed. Osteoporosis, or bone thinning after long steroid use, is one situation; cancer-related bone protection is another, and it changes the recommendation substantially.
• Other medications and conditions. Corticosteroids, drugs that suppress the immune system or block new blood vessel growth, diabetes and smoking are each associated with higher MRONJ risk. Mention them even if they seem unrelated.
• The state of your gums and any dentures. Active gum disease and a denture that rubs on thin bone are also associated with higher risk, and both can usually be addressed before surgery.
• Any previous jaw problems. A socket that healed slowly after an extraction, or a sore spot that never quite closed, is important history.

Each of these is a piece of information the dentist needs, not a reason to be turned away. An implant may still be a reasonable choice in selected cases; the point is to decide with the facts in view.

Working with the physician who prescribes the medication

With your permission, the dentist may contact the prescribing physician or ask you to carry a short written question to them. The dentist usually wants to confirm the drug, dose, schedule, start date and indication, and to learn whether the physician expects the medication to continue for years or to be reviewed soon. The patient information for some of these medications, including the RANKL inhibitor injection, advises a dental examination before starting and a conversation with the physician before dental treatment, so the physician will expect the question.

You may have read about "drug holidays," meaning a pause in the medication around surgery. Guidance is cautious here. The ADA states that there is insufficient evidence to recommend a holiday from osteoporosis medication for the purpose of preventing MRONJ. A pause also carries a cost, because the medication's job is fracture prevention. If a pause is ever discussed, it is the physician's decision, weighed against your fracture risk, and not something a patient should begin alone.

You may also have heard of a blood test said to predict who is at risk. The ADA's reading of the current evidence is that there is not enough support to use such markers to predict individual MRONJ risk, and this guide does not describe any laboratory score as a decision tool. The decision rests on the history above, the examination and imaging, and your own weighing of the risk.

What the examination determines, and what the alternatives are

An implant consultation looks at the bone available, the health of the gums, the bite, the neighboring teeth and your general health, usually with imaging. For someone on an osteoporosis medication, the examination also asks whether the site can be prepared with as little bone disturbance as possible, whether gum disease needs treating first, and whether any other extractions or grafting would add surgery on top of the implant. Good daily cleaning and regular dental care are described by the ADA as perhaps the best available way to lower MRONJ risk, so a hygiene plan is part of the preparation, not an afterthought.

Evidence on implant outcomes in people taking oral bisphosphonates for osteoporosis is limited but not discouraging. A systematic review and meta-analysis found that implant success was not reduced in these patients, while noting that the studies were few and of modest quality, and the oral surgeons' 2022 position paper describes the risk of implant-related osteonecrosis at osteoporosis doses as low, while noting that cases have been reported years after an implant was placed. "Limited" is the key word, and the dentist should say so during consent rather than promise an outcome.

If the balance tips against implant surgery, perhaps because of a cancer indication, many years of exposure or several added risk factors, there are other ways to replace a tooth. A fixed bridge anchors a replacement tooth to the neighboring teeth without surgery in bone. A removable partial denture avoids surgery as well, provided it is well fitted and checked regularly so it does not rub. And sometimes the best plan is to keep and repair a questionable tooth rather than remove it, because extraction is itself a bone procedure. Our guides on who may be a good candidate for an implant and implant or bridge for one missing tooth cover those trade-offs in more depth.

What the written plan should say, and the warning signs afterward

A written treatment plan for an implant in a patient on an antiresorptive medication should name the medication and indication as recorded, state that MRONJ risk was discussed and how it was described, note any physician correspondence, and list the warning signs to watch for after surgery. See what a written dental treatment plan should explain for the general shape of such a document.

After implant surgery, contact the office promptly if you notice:

• Exposed bone, a gray or white hard area visible in the gum, or a surgical site that is not closing after the expected healing time.
• Persistent pain, swelling or discharge at the site, or a bad taste that does not clear.
• Numbness or a heavy feeling in the lip, chin or jaw.
• A loose implant, or a nearby tooth loosening.

Some situations are medical emergencies and should not wait for a dental appointment. If you have difficulty breathing or swallowing, swelling that is spreading quickly across the face or into the neck, fever together with facial swelling, or bleeding that will not stop with firm pressure, call 911 or go to the nearest emergency department first.

The next step

Schedule an implant consultation and bring your full medication list, including anything you stopped in the past few years, and the name and contact details of the physician who manages your bone health. If you would like the office to coordinate with that physician, say so when you book, and ask how the office prefers to receive medical records and whether it would like the form below completed in advance. You can request an appointment online; a request is not a confirmed appointment, and the team follows up to arrange a time. For a broader picture of what an implant consultation should cover, see what a complete implant consultation should include.